These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 32391948

  • 1. Long-Term Outcomes With Teduglutide From a Single Center.
    Puello F, Wall E, Herlitz J, Lozano ES, Semrad C, Micic D.
    JPEN J Parenter Enteral Nutr; 2021 Feb; 45(2):318-322. PubMed ID: 32391948
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Predictors and timing of response to teduglutide in patients with short bowel syndrome dependent on parenteral support.
    Chen K, Joly F, Mu F, Kelkar SS, Olivier C, Xie J, Seidner DL.
    Clin Nutr ESPEN; 2021 Jun; 43():420-427. PubMed ID: 34024550
    [Abstract] [Full Text] [Related]

  • 4. Six-month outcomes of teduglutide treatment in adult patients with short bowel syndrome with chronic intestinal failure: A real-world French observational cohort study.
    Joly F, Seguy D, Nuzzo A, Chambrier C, Beau P, Poullenot F, Thibault R, Armengol Debeir L, Layec S, Boehm V, Lallemand J, Quilliot D, Schneider SM.
    Clin Nutr; 2020 Sep; 39(9):2856-2862. PubMed ID: 31932048
    [Abstract] [Full Text] [Related]

  • 5. Single-Center Experience with the Use of Teduglutide in Adult Patients with Short Bowel Syndrome.
    Lam K, Schwartz L, Batisti J, Iyer KR.
    JPEN J Parenter Enteral Nutr; 2018 Jan; 42(1):225-230. PubMed ID: 29505151
    [Abstract] [Full Text] [Related]

  • 6. Independence From Parenteral Nutrition and Intravenous Fluid Support During Treatment With Teduglutide Among Patients With Intestinal Failure Associated With Short Bowel Syndrome.
    Iyer KR, Kunecki M, Boullata JI, Fujioka K, Joly F, Gabe S, Pape UF, Schneider SM, Virgili Casas MN, Ziegler TR, Li B, Youssef NN, Jeppesen PB.
    JPEN J Parenter Enteral Nutr; 2017 Aug; 41(6):946-951. PubMed ID: 27875291
    [Abstract] [Full Text] [Related]

  • 7. Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.
    Jeppesen PB, Gabe SM, Seidner DL, Lee HM, Olivier C.
    Gastroenterology; 2018 Mar; 154(4):874-885. PubMed ID: 29174926
    [Abstract] [Full Text] [Related]

  • 8. Early use of teduglutide in paediatric patients with intestinal failure is associated with a greater response rate: a multicenter study.
    Germán-Díaz M, Alcolea A, Cabello V, Blasco-Alonso J, Rodríguez A, Galera R, García-Romero R, Romero C, González-Sacristán R, Redecillas-Ferreiro S, Moreno-Villares JM, Ramos-Boluda E.
    Eur J Pediatr; 2024 Aug; 183(8):3173-3182. PubMed ID: 38664251
    [Abstract] [Full Text] [Related]

  • 9. Teduglutide in short bowel syndrome patients: A way back to normal life?
    Harpain F, Schlager L, Hütterer E, Dawoud C, Kirchnawy S, Stift J, Krotka P, Stift A.
    JPEN J Parenter Enteral Nutr; 2022 Feb; 46(2):300-309. PubMed ID: 34614239
    [Abstract] [Full Text] [Related]

  • 10. Short-term clinical evaluation of teduglutide for patients with Crohn's disease on home parenteral support for postoperative short bowel syndrome with intestinal failure.
    Sato T, Uchino M, Takeuchi J, Fujihira Y, Shimizu K, Yokoyama K, Yagi S, Kaku K, Takashima Y, Ikenouchi M, Kojima K, Kawai M, Nagase K, Kamikozuru K, Yokoyama Y, Takagawa T, Ikeuchi H, Watanabe K, Shinzaki S.
    Clin Nutr; 2023 May; 42(5):722-731. PubMed ID: 37001195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety and Efficacy of Teduglutide (Gattex) in Patients With Crohn's Disease and Need for Parenteral Support Due to Short Bowel Syndrome-associated Intestinal Failure.
    Kochar B, Long MD, Shelton E, Young L, Farraye FA, Yajnik V, Herfarth H.
    J Clin Gastroenterol; 2017 Jul; 51(6):508-511. PubMed ID: 27433811
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Quality of life in patients with short bowel syndrome treated with the new glucagon-like peptide-2 analogue teduglutide--analyses from a randomised, placebo-controlled study.
    Jeppesen PB, Pertkiewicz M, Forbes A, Pironi L, Gabe SM, Joly F, Messing B, Loth S, Youssef NN, Heinze H, Berghöfer P.
    Clin Nutr; 2013 Oct; 32(5):713-21. PubMed ID: 23587733
    [Abstract] [Full Text] [Related]

  • 16. Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome.
    Jeppesen PB, Gilroy R, Pertkiewicz M, Allard JP, Messing B, O'Keefe SJ.
    Gut; 2011 Jul; 60(7):902-14. PubMed ID: 21317170
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Long-term teduglutide associated with improved response in pediatric short bowel syndrome-associated intestinal failure.
    Wales PW, Hill S, Robinson I, Raphael BP, Matthews C, Cohran V, Carter B, Venick R, Kocoshis S.
    J Pediatr Gastroenterol Nutr; 2024 Aug; 79(2):290-300. PubMed ID: 38873891
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.